Serum interleukin-17 as a diagnostic and prognostic marker for non-small cell lung cancer

Biomarkers

Volumn 19, Issue 4, 2014, Pages 287-290

  Xu, Chunhua ^a   Hao, Keke ^a   Yu, Like ^a   Zhang, Xiuwei ^b  

^a NANJING CHEST HOSPITAL   (China)

^b THE AFFILIATED JIANGNING HOSPITAL OF NANJING MEDICAL UNIVERSITY   (China)

Author keywords

Diagnosis; Interleukin 17; Non small cell lung cancer; Prognosis

Indexed keywords

INTERLEUKIN 17; TUMOR MARKER; C REACTIVE PROTEIN;

ADULT; ARTICLE; BLOOD LEVEL; CANCER PATIENT; CANCER PROGNOSIS; CANCER SURVIVAL; CONTROLLED STUDY; DIAGNOSTIC VALUE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MEASUREMENT; AGED; BLOOD; CARCINOMA, NON-SMALL-CELL LUNG; LUNG NEOPLASMS; METABOLISM; MIDDLE AGED; PATHOLOGY; PROGNOSIS; SURVIVAL;

AGED; C-REACTIVE PROTEIN; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; HUMANS; INTERLEUKIN-17; LUNG NEOPLASMS; MALE; MIDDLE AGED; PROGNOSIS; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 84901338357     PISSN: 1354750X     EISSN: 13665804     Source Type: Journal    
DOI: 10.3109/1354750X.2014.908954     Document Type: Article

References (21)

1. Benchetrit F, Ciree A, Vives V, et al. (2002). Interleukin-17 inhibits tumor cell growThby means of a T-cell-Dependent mechanism. Blood 99:2114-21. (Pubitemid 34525496
2. Chen Z, Wang T, Cai L, et al. (2012). Clinicopathological significance of non-small cell lung cancer wiThhigh prevalence of Oct-4 tumor cells. J Exp Clin Cancer Res 31:10
3. Dong C. (2008). TH17 cells in development: An updated view of their molecular identity and genetic programming. Nat Rev Immunol 8: 337-548
4. Droeser RA, GüThU, Eppenberger-Castori S, et al. (2013). High IL-17-positive tumor immune cell infiltration is indicative for chemosensitivity of ovarian carcinoma. J Cancer Res Clin Oncol 139:1295-302
5. Garley M, Jabłońska E, Grabowska SZ, Piotrowski L. (2009). IL-17 family cytokines in neutrophils of patients wiThoral epithelial squamous cell carcinoma. Neoplasma 56:96-100
6. Grunnet M, Sorensen JB. (2010). Carcinoembryonic antigen (CEA) as tumor marker in lung cancer. Lung Cancer 76:138-43
7. Jemal A, Siegel R, Xu J, Ward E. (2010). Cancer statistics, 2010. CA Cancer J Clin 60:277-300
8. Le Gouvello S, Bastuji-Garin S, Aloulou N, et al. (2008). High prevalence of Foxp3 and IL17 in MMR-proficient colorectal carcinomas. Gut 57:772-9. (Pubitemid 351716970
9. Liao R1, Sun J, Wu H, et al. (2013). High expression of IL-17 and IL-17RE associate wiThpoor prognosis of hepatocellular carcinoma. J Exp Clin Cancer Res 32:3
10. Miyahara YK, Odunsi K, Chen W, et al. (2008). Generation and regulation of human CD4+ IL-17-producing T cells in ovarian cancer. Proc Natl Acad Sci USA 105:15505-10
11. Moseley TA, Haudenschild DR, Rose L, Reddi AH. (2003). Interleukin-17 family and IL-17 receptors. Cytokine GrowThFactor Rev 14: 155-74. (Pubitemid 36389528
12. Nisman B, Biran H, Ramu N, et al. (2009). The diagnostic and prognostic value of ProGRP in lung cancer. Anticancer Res 29: 4827-32
13. Numasaki M, Watanabe M, Suzuki T, et al. (2005). IL-17 enhances the net angiogenic activity and in vivo growThof human non-small cell lung cancer in SCID mice through promoting CXCR-2-Dependent angiogenesis. J Immunol 175:6177-89. (Pubitemid 41508106
14. Oguz A, Unal D, Tasdemir A, et al. (2013). Lack of any association between blood groups and lung cancer, independent of histology. Asian Pac J Cancer Prev 14:453-6
15. Okamura K, Takayama K, Izumi M, et al. (2013). Diagnostic value of CEA and CYFRA 21-1 tumor markers in primary lung cancer. Lung Cancer 80:45-9
16. Prabhala RH, Pelluru D, Fulciniti M, et al. (2010). Elevated IL-17 produced by TH17 cells promotes myeloma growThand inhibits immune function in multiple myeloma. Blood 115:5385-92
17. Smith RA, Cokkinides V, Brawley OW. (2009). Cancer screening in the United States, 2009: A review of current American Cancer Society guidelines and issues in cancer screening. CA Cancer J Clin 59:27-41
18. Steiner GE, Newman ME, Paikl D, et al. (2002). Expression and function of pro-inflammatory interleukin IL-17 and IL-17 receptor in normal, benign hyperplastic, and malignant prostate. Prostate 56:171-82
19. Tufman A, Huber RM. (2010). Biological markers in lung cancer: A clinician's perspective. Cancer Biomark 6:123-35
20. Zhang JP, Yan J, Xu J, et al. (2009). Increased intratumoral IL-17-producing cells correlate wiThpoor survival in hepatocellular carcinoma patients. J Hepatol 50:980-9
21. Zhu X, Mulcahy LA, Mohammed RA, et al. (2008). IL-17 expression by breast-cancer-Associated macrophages: IL-17 promotes invasiveness of breast cancer cell lines. Breast Cancer Res 10:R95